Home/Therapeutic Areas/Radiopharmaceuticals

☢️

Radiopharmaceuticals

Radioligand therapies and nuclear medicine approaches for targeted cancer treatment and diagnostic imaging.

Companies

0

Pipeline Drugs

11

Key People

3

Radiopharmaceuticals Pipeline (11 drugs)

Pre-clinical: 2Commercial: 2Phase 3: 2Clinical Development: 2Phase 2b: 1Multiple Phases: 1Approved: 1

Drug	Company	Indication	Phase	Status
Radspherin	Oncoinvent	Peritoneal metastasis from ovarian cancer	Phase 2b	Ongoing — randomized controlled trial
OI-1 Antibody	Oncoinvent	PTK7-targeting (various cancers)	Pre-clinical	Available for partnering
Multiple Sclerosis Portfolio	Biogen	Multiple Sclerosis	Commercial	Active
Spinal Muscular Atrophy Program	Biogen	Spinal Muscular Atrophy	Commercial	Active
Alzheimer's Disease Program	Biogen	Alzheimer's Disease and Dementia	Phase 3	Active
ALS Program	Biogen	Amyotrophic Lateral Sclerosis	Multiple Phases	Active
Friedreich Ataxia Treatment	Biogen	Friedreich Ataxia	Approved	Active
Lupus Program	Biogen	Systemic Lupus	Phase 3	Active
Postpartum Depression Program	Biogen	Postpartum Depression	Clinical Development	Active
Kidney Disease Portfolio	Biogen	Immune-mediated Kidney Disease	Clinical Development	Active
ASO Candidates for SMA	Biogen	Spinal Muscular Atrophy	Pre-clinical	Active

Key People in Radiopharmaceuticals

Anders Månsson

Chief Executive Officer

Chief Financial Officer

Diana Gallagher

MD - Biology and Humanity Intersection

Related Therapeutic Areas

🎯Oncology 🛡️Immunotherapy 🧬Immunology 🧠Neuroscience 💎Rare Diseases ❤️Cardiovascular